1.The Profile of Early Sedation Depth and Clinical Outcomes of Mechanically Ventilated Patients in Korea
Dong-gon HYUN ; Jee Hwan AHN ; Ha-Yeong GIL ; Chung Mo NAM ; Choa YUN ; Jae-Myeong LEE ; Jae Hun KIM ; Dong-Hyun LEE ; Ki Hoon KIM ; Dong Jung KIM ; Sang-Min LEE ; Ho-Geol RYU ; Suk-Kyung HONG ; Jae-Bum KIM ; Eun Young CHOI ; JongHyun BAEK ; Jeoungmin KIM ; Eun Jin KIM ; Tae Yun PARK ; Je Hyeong KIM ; Sunghoon PARK ; Chi-Min PARK ; Won Jai JUNG ; Nak-Jun CHOI ; Hang-Jea JANG ; Su Hwan LEE ; Young Seok LEE ; Gee Young SUH ; Woo-Sung CHOI ; Keu Sung LEE ; Hyung Won KIM ; Young-Gi MIN ; Seok Jeong LEE ; Chae-Man LIM
Journal of Korean Medical Science 2023;38(19):e141-
Background:
Current international guidelines recommend against deep sedation as it is associated with worse outcomes in the intensive care unit (ICU). However, in Korea the prevalence of deep sedation and its impact on patients in the ICU are not well known.
Methods:
From April 2020 to July 2021, a multicenter, prospective, longitudinal, noninterventional cohort study was performed in 20 Korean ICUs. Sedation depth extent was divided into light and deep using a mean Richmond Agitation–Sedation Scale value within the first 48 hours. Propensity score matching was used to balance covariables; the outcomes were compared between the two groups.
Results:
Overall, 631 patients (418 [66.2%] and 213 [33.8%] in the deep and light sedation groups, respectively) were included. Mortality rates were 14.1% and 8.4% in the deep and light sedation groups (P = 0.039), respectively. Kaplan-Meier estimates showed that time to extubation (P < 0.001), ICU length of stay (P = 0.005), and death P = 0.041) differed between the groups. After adjusting for confounders, early deep sedation was only associated with delayed time to extubation (hazard ratio [HR], 0.66; 95% confidence inter val [CI], 0.55– 0.80; P < 0.001). In the matched cohort, deep sedation remained significantly associated with delayed time to extubation (HR, 0.68; 95% 0.56–0.83; P < 0.001) but was not associated with ICU length of stay (HR, 0.94; 95% CI, 0.79–1.13; P = 0.500) and in-hospital mortality (HR, 1.19; 95% CI, 0.65–2.17; P = 0.582).
Conclusion
In many Korean ICUs, early deep sedation was highly prevalent in mechanically ventilated patients and was associated with delayed extubation, but not prolonged ICU stay or in-hospital death.
2.Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis
Na Young LEE ; Min Jea SHIN ; Gi Soo YOUN ; Sang Jun YOON ; Ye Rin CHOI ; Hyeong Seop KIM ; Haripriya GUPTA ; Sang Hak HAN ; Byoung Kook KIM ; Do Yup LEE ; Tae Sik PARK ; Hotaik SUNG ; Byung Yong KIM ; Ki Tae SUK
Clinical and Molecular Hepatology 2021;27(1):110-124
Background/Aims:
Nonalcoholic fatty liver disease (NAFLD) is closely related to gut-microbiome. There is a paucity of research on which strains of gut microbiota affect the progression of NAFLD. This study explored the NAFLD-associated microbiome in humans and the role of Lactobacillus in the progression of NAFLD in mice.
Methods:
The gut microbiome was analyzed via next-generation sequencing in healthy people (n=37) and NAFLD patients with elevated liver enzymes (n=57). Six-week-old male C57BL/6J mice were separated into six groups (n=10 per group; normal, Western, and four Western diet + strains [109 colony-forming units/g for 8 weeks; L. acidophilus, L. fermentum, L. paracasei, and L. plantarum]). Liver/body weight ratio, liver pathology, serum analysis, and metagenomics in the mice were examined.
Results:
Compared to healthy subjects (1.6±4.3), NAFLD patients showed an elevated Firmicutes/Bacteroidetes ratio (25.0±29.0) and a reduced composition of Akkermansia and L. murinus (P<0.05). In the animal experiment, L. acidophilus group was associated with a significant reduction in liver/body weight ratio (5.5±0.4) compared to the Western group (6.2±0.6) (P<0.05). L. acidophilus (41.0±8.6), L. fermentum (44.3±12.6), and L. plantarum (39.0±7.6) groups showed decreased cholesterol levels compared to the Western group (85.7±8.6) (P<0.05). In comparison of steatosis, L. acidophilus (1.9±0.6), L. plantarum (2.4±0.7), and L. paracasei (2.0±0.9) groups showed significant improvement of steatosis compared to the Western group (2.6±0.5) (P<0.05).
Conclusions
Ingestion of Lactobacillus, such as L. acidophilus, L. fermentum, and L. plantarum, ameliorates the progression of nonalcoholic steatosis by lowering cholesterol. The use of Lactobacillus can be considered as a useful strategy for the treatment of NAFLD.
3.Trends in the prevalence of chronic liver disease in theKorean adult population, 1998–2017
Seung Ha PARK ; Lindsay D. PLANK ; Ki Tae SUK ; Yong Eun PARK ; Jin LEE ; Joon Hyuk CHOI ; Nae Yun HEO ; Jongha PARK ; Tae Oh KIM ; Young Soo MOON ; Hyun Kuk KIM ; Hang Jea JANG ; Ha Young PARK ; Dong Joon KIM
Clinical and Molecular Hepatology 2020;26(2):209-215
Background/Aims:
Data on the trends in the prevalence of chronic liver disease (CLD) in Korea are scarce. This study aimed to evaluate whether the CLD prevalence changed between 1998–2001 and 2016–2017.
Methods:
Data were extracted from the Korea National Health and Nutrition Examination Survey (1998–2001 to 2016– 2017; n=25,893). Non-alcoholic fatty liver disease (NAFLD) was defined as a hepatic steatosis index >36 in the absence of any other evidence of CLD. The definition of alcohol-related liver disease (ALD) was excessive alcohol consumption (≥210 g/week for men and ≥140 g/week for women) and an ALD/NAFLD index >0.
Results:
The prevalence of NAFLD increased from 18.6% (95% confidence interval [CI], 17.8–19.5%) in 1998–2001 to 21.5% (95% CI, 20.6–22.6%) in 2016–2017. During the same time period, increases were observed in the prevalence of obesity (27.0 vs. 35.1%), central obesity (29.4 vs. 36.0%), diabetes (7.5 vs. 10.6%), and excessive drinking (7.3 vs. 10.5%). ALD prevalence also increased from 3.8% (95% CI, 3.4–4.2%) to 7.0% (95% CI, 6.4–7.6%). In contrast, chronic hepatitis B decreased from 5.1% (95% CI, 4.6–5.5%) to 3.4% (95% CI, 3.0–3.8%). The prevalence of chronic hepatitis C was approximately 0.3% in 2016–2017.
Conclusions
The prevalence of NAFLD and ALD increase among Korean adults. Our results suggest potential targets for interventions to reduce the future burden of CLD.
4.Which strategy is better for resectable synchronous liver metastasis from colorectal cancer, simultaneous surgery, or staged surgery? Multicenter retrospective analysis
Bong Hyeon KYE ; Suk Hwan LEE ; Woon Kyung JEONG ; Chang Sik YU ; In Ja PARK ; Hyeong Rok KIM ; Jin KIM ; In Kyu LEE ; Ki Jea PARK ; Hong Jo CHOI ; Ho Young KIM ; Jeong Heum BAEK ; Yoon Suk LEE
Annals of Surgical Treatment and Research 2019;97(4):184-193
PURPOSE: The optimal treatment for synchronous liver metastasis (LM) from colorectal cancer (CRC) depends on various factors. The present study was intended to investigate the oncologic outcome according to the time of resection of metastatic lesions. METHODS: Data from patients who underwent treatment with curative intent for primary CRC and synchronous LM between 2004 and 2009 from 9 university hospitals in Korea were collected retrospectively. One hundred forty-three patients underwent simultaneous resection for primary CRC and synchronous LM (simultaneous surgery group), and 65 patients were treated by 2-stage operation (staged surgery group). RESULTS: The mean follow-up length was 41.2 ± 24.6 months. In the extent of resection for hepatic metastasis, major hepatectomy was more frequently performed in staged surgery group (33.8% vs. 8.4%, P < 0.001). The rate of severe complications of Clavien-Dindo classification grade III or more was not significantly different between the 2 groups. The 3-year overall survival (OS) rate was 85.0% in staged surgery group and 69.4% in simultaneous surgery group (P = 0.013), and the 3-year recurrence-free survival (RFS) rate was 46.4% in staged surgery group and 30.2% in simultaneous surgery group (P = 0.143). In subgroup analysis based on the location of primary CRC, the benefit of staged surgery for OS and RFS was clearly shown in rectal cancer (P = 0.021 and P = 0.015). CONCLUSION: Based on our results, staged surgery with or without neoadjuvant chemotherapy should be considered for resectable synchronous LM from CRC, especially in rectal cancer, as a safe and fairly promising option.
Classification
;
Colorectal Neoplasms
;
Drug Therapy
;
Follow-Up Studies
;
Hepatectomy
;
Hospitals, University
;
Humans
;
Korea
;
Liver
;
Neoplasm Metastasis
;
Rectal Neoplasms
;
Retrospective Studies
5.Clinical and Angiographic Outcomes of the First Korean-made Sirolimus-Eluting Coronary Stent with Abluminal Bioresorbable Polymer.
Hyoung Mo YANG ; Kyoung Woo SEO ; Junghan YOON ; Hyo Soo KIM ; Kiyuk CHANG ; Hong Seok LIM ; Byoung Joo CHOI ; So Yeon CHOI ; Myeong Ho YOON ; Seung Hwan LEE ; Sung Gyun AHN ; Young Jin YOUN ; Jun Won LEE ; Bon Kwon KOO ; Kyung Woo PARK ; Han Mo YANG ; Jung Kyu HAN ; Ki Bae SEUNG ; Wook Sung CHUNG ; Pum Joon KIM ; Yoon Seok KOH ; Hun Jun PARK ; Seung Jea TAHK
Korean Circulation Journal 2017;47(6):898-906
BACKGROUND AND OBJECTIVES: This trial evaluated the safety and efficacy of the Genoss drug-eluting coronary stent. METHODS: This study was a prospective, multicenter, randomized trial with a 1:1 ratio of Genoss drug-eluting stent (DES)™ and Promus Element™. Inclusion criteria were the presence of stable angina, unstable angina, or silent ischemia. Angiographic inclusion criteria were de novo coronary stenotic lesion with diameter stenosis >50%, reference vessel diameter of 2.5–4.0 mm, and lesion length ≤40 mm. The primary endpoint was in-stent late lumen loss at 9-month quantitative coronary angiography follow-up. Secondary endpoints were in-segment late lumen loss, binary restenosis rate, death, myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), and stent thrombosis during 9 months of follow-up. RESULTS: We enrolled 38 patients for the Genoss DES™ group and 39 patients for the Promus Element™ group. In-stent late lumen loss at 9 months was not significantly different between the 2 groups (0.11±0.25 vs. 0.16±0.43 mm, p=0.567). There was no MI or stent thrombosis in either group. The rates of death (2.6% vs. 0%, p=0.494), TLR (2.6% vs. 2.6%, p=1.000), and TVR (7.9% vs. 2.6%, p=0.358) at 9 months were not significantly different. CONCLUSION: This first-in-patient study of the Genoss DES™ stent showed excellent angiographic outcomes for in-stent late lumen loss and major adverse cardiac events over a 9-month follow-up.
Angina, Stable
;
Angina, Unstable
;
Constriction, Pathologic
;
Coronary Angiography
;
Coronary Artery Disease
;
Drug-Eluting Stents
;
Follow-Up Studies
;
Humans
;
Ischemia
;
Mortality
;
Myocardial Infarction
;
Polymers*
;
Prospective Studies
;
Sirolimus
;
Stents*
;
Thrombosis
6.Bioresorbable Vascular Scaffold Korean Expert Panel Report.
Jung Min AHN ; Duk Woo PARK ; Sung Jin HONG ; Young Keun AHN ; Joo Yong HAHN ; Won Jang KIM ; Soon Jun HONG ; Chang Wook NAM ; Do Yoon KANG ; Seung Yul LEE ; Woo Jung CHUN ; Jung Ho HEO ; Deok Kyu CHO ; Jin Won KIM ; Sung Ho HER ; Sang Wook KIM ; Sang Yong YOO ; Myeong Ki HONG ; Seung Jea TAHK ; Kee Sik KIM ; Moo Hyun KIM ; Yangsoo JANG ; Seung Jung PARK
Korean Circulation Journal 2017;47(6):795-810
Bioresorbable vascular scaffold (BRS) is an innovative device that provides structural support and drug release to prevent early recoil or restenosis, and then degrades into nontoxic compounds to avoid late complications related with metallic drug-eluting stents (DESs). BRS has several putative advantages. However, recent randomized trials and registry studies raised clinical concerns about the safety and efficacy of first generation BRS. In addition, the general guidance for the optimal practice with BRS has not been suggested due to limited long-term clinical data in Korea. To address the safety and efficacy of BRS, we reviewed the clinical evidence of BRS implantation, and suggested the appropriate criteria for patient and lesion selection, scaffold implantation technique, and management.
Coronary Disease
;
Drug Liberation
;
Drug-Eluting Stents
;
Humans
;
Korea
;
Stents
;
Thrombosis
7.Use of Extracorporeal Membrane Oxygenation in a Fulminant Course of Amniotic Fluid Embolism Syndrome Immediately after Cesarean Delivery.
Jae Ha LEE ; Hang Jea JANG ; Jin Han PARK ; Yong Kyun KIM ; Ho Ki MIN ; Sun Young KIM ; Hyun kuk KIM
Korean Journal of Critical Care Medicine 2016;31(3):256-261
Amniotic fluid embolism is rare but is one of the most catastrophic complications in the peripartum period. This syndrome is caused by a maternal anaphylactic reaction to the introduction of fetal material into the pulmonary circulation. When amniotic fluid embolism is suspected, the immediate application of extracorporeal mechanical circulatory support such as veno-arterial extracorporeal membrane oxygenation (ECMO) or cardiopulmonary bypass should be considered. Without the application of extracorporeal mechanical circulatory support, medical supportive care might not be sufficient to maintain cardiopulmonary stabilization in severe cases of amniotic fluid embolism. In this report, we present the case of a 36-year-old pregnant woman who developed an amniotic fluid embolism immediately after a cesarean section. Her catastrophic event started with the sudden onset of severe hypoxia, followed by circulatory collapse within 8 minutes. The veno-arterial mode of extracorporeal membrane oxygenation was initiated immediately. She was successfully resuscitated but with impaired cognitive function. Thus, urgent ECMO should be considered when amniotic fluid embolism syndrome is suspected in patients presenting acute cardiopulmonary collapse.
Adult
;
Amniotic Fluid*
;
Anaphylaxis
;
Anoxia
;
Cardiopulmonary Bypass
;
Cesarean Section
;
Cognition
;
Embolism, Amniotic Fluid*
;
Extracorporeal Membrane Oxygenation*
;
Female
;
Humans
;
Peripartum Period
;
Pregnancy
;
Pregnant Women
;
Pulmonary Circulation
;
Shock
8.Clinical Outcomes in Patients with Deferred Coronary Lesions according to Disease Severity Assessed by Fractional Flow Reserve.
Ki Bum WON ; Chang Wook NAM ; Yun Kyeong CHO ; Hyuck Jun YOON ; Hyoung Seob PARK ; Hyungseop KIM ; Seongwook HAN ; Seung Ho HUR ; Yoon Nyun KIM ; Sang Hyun PARK ; Jung Kyu HAN ; Bon Kwon KOO ; Hyo Soo KIM ; Joon Hyung DOH ; Sung Yun LEE ; Hyoung Mo YANG ; Hong Seok LIM ; Myeong Ho YOON ; Seung Jea TAHK ; Kwon Bae KIM
Journal of Korean Medical Science 2016;31(12):1929-1936
Data on the clinical outcomes in deferred coronary lesions according to functional severity have been limited. This study evaluated the clinical outcomes of deferred lesions according to fractional flow reserve (FFR) grade using Korean FFR registry data. Among 1,294 patients and 1,628 lesions in Korean FFR registry, 665 patients with 781 deferred lesions were included in this study. All participants were consecutively categorized into 4 groups according to FFR; group 1: ≥ 0.96 (n = 56), group 2: 0.86–0.95 (n = 330), group 3: 0.81–0.85 (n = 170), and group 4: ≤ 0.80 (n = 99). Primary endpoint was major adverse cardiac events (MACE), a composite of all-cause death, myocardial infarction, and target vessel revascularization. The median follow-up period was 2.1 years. During follow-up, the incidence of MACE in groups 1–4 was 1.8%, 7.6%, 8.8%, and 13.1%, respectively. Compared to group 1, the cumulative rate by Kaplan-Meier analysis of MACE was not different for groups 2 and 3. However, group 4 had higher cumulative rate of MACE compared to group 1 (log-rank P = 0.013). In the multivariate Cox hazard models, only FFR (hazard ratio [HR], 0.95; P = 0.005) was independently associated with MACE among all participants. In contrast, previous history of percutaneous coronary intervention (HR, 2.37; P = 0.023) and diagnosis of acute coronary syndrome (ACS) (HR, 2.35; P = 0.015), but not FFR, were independent predictors for MACE in subjects with non-ischemic (FFR ≥ 0.81) deferred coronary lesions. Compared to subjects with ischemic deferred lesions, clinical outcomes in subjects with non-ischemic deferred lesions according to functional severity are favorable. However, longer-term follow-up may be necessary.
Acute Coronary Syndrome
;
Coronary Artery Disease
;
Diagnosis
;
Follow-Up Studies
;
Humans
;
Incidence
;
Kaplan-Meier Estimate
;
Myocardial Infarction
;
Percutaneous Coronary Intervention
;
Prognosis
;
Proportional Hazards Models
9.Use of Extracorporeal Membrane Oxygenation in a Fulminant Course of Amniotic Fluid Embolism Syndrome Immediately after Cesarean Delivery
Jae Ha LEE ; Hang Jea JANG ; Jin Han PARK ; Yong Kyun KIM ; Ho Ki MIN ; Sun Young KIM ; Hyun kuk KIM
The Korean Journal of Critical Care Medicine 2016;31(3):256-261
Amniotic fluid embolism is rare but is one of the most catastrophic complications in the peripartum period. This syndrome is caused by a maternal anaphylactic reaction to the introduction of fetal material into the pulmonary circulation. When amniotic fluid embolism is suspected, the immediate application of extracorporeal mechanical circulatory support such as veno-arterial extracorporeal membrane oxygenation (ECMO) or cardiopulmonary bypass should be considered. Without the application of extracorporeal mechanical circulatory support, medical supportive care might not be sufficient to maintain cardiopulmonary stabilization in severe cases of amniotic fluid embolism. In this report, we present the case of a 36-year-old pregnant woman who developed an amniotic fluid embolism immediately after a cesarean section. Her catastrophic event started with the sudden onset of severe hypoxia, followed by circulatory collapse within 8 minutes. The veno-arterial mode of extracorporeal membrane oxygenation was initiated immediately. She was successfully resuscitated but with impaired cognitive function. Thus, urgent ECMO should be considered when amniotic fluid embolism syndrome is suspected in patients presenting acute cardiopulmonary collapse.
Adult
;
Amniotic Fluid
;
Anaphylaxis
;
Anoxia
;
Cardiopulmonary Bypass
;
Cesarean Section
;
Cognition
;
Embolism, Amniotic Fluid
;
Extracorporeal Membrane Oxygenation
;
Female
;
Humans
;
Peripartum Period
;
Pregnancy
;
Pregnant Women
;
Pulmonary Circulation
;
Shock
10.The Korean guideline for cervical cancer screening.
Kyung Jin MIN ; Yoon Jae LEE ; Mina SUH ; Chong Woo YOO ; Myong Cheol LIM ; Jaekyung CHOI ; Moran KI ; Yong Man KIM ; Jae Weon KIM ; Jea Hoon KIM ; Eal Whan PARK ; Hoo Yeon LEE ; Sung Chul LIM ; Chi Heum CHO ; Sung Ran HONG ; Ji Yeon DANG ; Soo Young KIM ; Yeol KIM ; Won Chul LEE ; Jae Kwan LEE
Journal of the Korean Medical Association 2015;58(5):398-407
The incidence rate of cervical cancer in Korea is still higher than in other developed countries, notwithstanding the national mass screening program. Furthermore, a new method has been introduced in cervical cancer screening. Therefore, the committee for cervical cancer screening in Korea updated the recommendation statement established in 2002. The new version of the guideline was developed by the committee using evidence-based methods. The committee reviewed the evidence for the benefits and harms of the Papanicolaou test, liquid-based cytology, and human papilloma virus (HPV) testing, and reached conclusions after deliberation. The committee recommends screening for cervical cancer with cytology (papanicolaou test or liquid-based cytology) every three years in women older than 20 years of age (recommendation A). The combination test (cytology with HPV test) is optionally recommended after taking into consideration individual risk or preference (recommendation C). The current evidence for primary HPV screening is insufficient to assess the benefits and harms of cervical cancer screening (recommendation I). Cervical cancer screening can be terminated at the age of 74 years if more than three consecutive negative cytology reports have been confirmed within ten years (recommendation D).
Developed Countries
;
Female
;
Humans
;
Incidence
;
Korea
;
Mass Screening*
;
Papanicolaou Test
;
Papilloma
;
Uterine Cervical Neoplasms*

Result Analysis
Print
Save
E-mail